Filippo Birocchi
0000-0002-5214-233X
Publication & Citation Trends
Publications
0 total
Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory Diarrhea.
Cited by 0
Semantic Scholar
Ibrutinib and PD-1 blockade potentiate mesothelin-targeting CAR-T cell therapy in preclinical models of pancreatic cancer.
Cited by 0
Semantic Scholar
CAR-T cell therapy targeting MUC17 in gastric tumors
Cited by 0
Semantic Scholar
Triple base-edited dual targeting CD70/33 CAR T cells to avoid cytokine-mediated resistance in Acute Myeloid Leukemia
Cited by 0
Semantic Scholar
Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time
Cited by 4
Semantic Scholar
Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma
Cited by 1
Semantic Scholar
Sialylated CD43 is a glyco-immune checkpoint for macrophage phagocytosis
Cited by 1
Semantic Scholar
Drug tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms
Cited by 1
Semantic Scholar
Research Topics
CAR-T cell therapy research
(81)
Monoclonal and Polyclonal Antibodies Research
(17)
Immune Cell Function and Interaction
(7)
Virus-based gene therapy research
(6)
Viral Infectious Diseases and Gene Expression in Insects
(5)
Affiliations
Broad Institute
Harvard University
Vita-Salute San Raffaele University
Massachusetts General Hospital
Dana-Farber/Harvard Cancer Center